JP2012502975A - 治療において有用なアミド化合物 - Google Patents
治療において有用なアミド化合物 Download PDFInfo
- Publication number
- JP2012502975A JP2012502975A JP2011527444A JP2011527444A JP2012502975A JP 2012502975 A JP2012502975 A JP 2012502975A JP 2011527444 A JP2011527444 A JP 2011527444A JP 2011527444 A JP2011527444 A JP 2011527444A JP 2012502975 A JP2012502975 A JP 2012502975A
- Authority
- JP
- Japan
- Prior art keywords
- pyrazole
- carboxamide
- cyanophenyl
- isopropyl
- cyclopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 Cc1c(C(NCC(*)(*)O)=O)[n](C2CC2)nc1-c(cc1)ccc1C#* Chemical compound Cc1c(C(NCC(*)(*)O)=O)[n](C2CC2)nc1-c(cc1)ccc1C#* 0.000 description 34
- VKBOJTQZXPRWSY-UHFFFAOYSA-N CC(C)(CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1COCC1)=O)O Chemical compound CC(C)(CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1COCC1)=O)O VKBOJTQZXPRWSY-UHFFFAOYSA-N 0.000 description 2
- OOJXSVJVUKKWLL-UHFFFAOYSA-N CC(C)C(N(C1)CC1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O Chemical compound CC(C)C(N(C1)CC1NC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O)=O OOJXSVJVUKKWLL-UHFFFAOYSA-N 0.000 description 1
- IQQPXUVLKVXGGM-YFHOEESVSA-N CC(C)N(C(C1C)C(NCC2CC2)=O)N=C1C(/C=C\C(C#N)=C(C)C)=C Chemical compound CC(C)N(C(C1C)C(NCC2CC2)=O)N=C1C(/C=C\C(C#N)=C(C)C)=C IQQPXUVLKVXGGM-YFHOEESVSA-N 0.000 description 1
- GNARTZOWIAVVSR-OKFRBQRWSA-N CC(C)N/C(/C(NCC(C)O)=O)=C(\C(c(cc1)ccc1C#N)=N)/C#N Chemical compound CC(C)N/C(/C(NCC(C)O)=O)=C(\C(c(cc1)ccc1C#N)=N)/C#N GNARTZOWIAVVSR-OKFRBQRWSA-N 0.000 description 1
- QYDGVWGFJZRANB-UHFFFAOYSA-N CC(C)NC(c1c(C)c(-c(cc2)cc(C)c2C#N)n[n]1C(C)C)=O Chemical compound CC(C)NC(c1c(C)c(-c(cc2)cc(C)c2C#N)n[n]1C(C)C)=O QYDGVWGFJZRANB-UHFFFAOYSA-N 0.000 description 1
- ACRHATDPJUUOIQ-UHFFFAOYSA-N CC(C)[n](c(C(NC(CC1)CS1(=O)=O)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC(CC1)CS1(=O)=O)=O)c1C2CC2)nc1-c(cc1)ccc1C#N ACRHATDPJUUOIQ-UHFFFAOYSA-N 0.000 description 1
- YEWVTHULFRGMBO-UHFFFAOYSA-N CC(C)[n](c(C(NC1CC1)=O)c1C#N)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC1CC1)=O)c1C#N)nc1-c(cc1)ccc1C#N YEWVTHULFRGMBO-UHFFFAOYSA-N 0.000 description 1
- FCDGFMMLLIREBJ-UHFFFAOYSA-N CC(C)[n](c(C(NC1CC1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC1CC1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N FCDGFMMLLIREBJ-UHFFFAOYSA-N 0.000 description 1
- OZSSUUDDOJZMMU-UHFFFAOYSA-N CC(C)[n](c(C(NC1CCC1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NC1CCC1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N OZSSUUDDOJZMMU-UHFFFAOYSA-N 0.000 description 1
- JSUMBIGESBYGTF-UHFFFAOYSA-N CC(C)[n](c(C(NCC(C)(C)O)=O)c1C#N)nc1-c(cc1C)ccc1C#N Chemical compound CC(C)[n](c(C(NCC(C)(C)O)=O)c1C#N)nc1-c(cc1C)ccc1C#N JSUMBIGESBYGTF-UHFFFAOYSA-N 0.000 description 1
- WCXVUYXIGPFOGB-UHFFFAOYSA-N CC(C)[n](c(C(NCCC1CC1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NCCC1CC1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N WCXVUYXIGPFOGB-UHFFFAOYSA-N 0.000 description 1
- QDWUTPPZHINRDL-UHFFFAOYSA-N CC(C)[n](c(C(NCc1c[n](C)nc1)=O)c1C2CC2)nc1-c(cc1)ccc1N Chemical compound CC(C)[n](c(C(NCc1c[n](C)nc1)=O)c1C2CC2)nc1-c(cc1)ccc1N QDWUTPPZHINRDL-UHFFFAOYSA-N 0.000 description 1
- BJRLXZSHCGSCEJ-UHFFFAOYSA-N CC(C)[n](c(C(NCc1ncncc1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(NCc1ncncc1)=O)c1C2CC2)nc1-c(cc1)ccc1C#N BJRLXZSHCGSCEJ-UHFFFAOYSA-N 0.000 description 1
- FSOZMSNFZLKMOX-UHFFFAOYSA-N CC(C)[n](c(C(OC(C)(C)C)=O)c1Cl)nc1-c(cc1)ccc1C#N Chemical compound CC(C)[n](c(C(OC(C)(C)C)=O)c1Cl)nc1-c(cc1)ccc1C#N FSOZMSNFZLKMOX-UHFFFAOYSA-N 0.000 description 1
- RGDNMZSUCZOCPT-UHFFFAOYSA-N CC(C)[n](c(C(OC)=O)c1C)nc1-c(cc1C)ccc1C#N Chemical compound CC(C)[n](c(C(OC)=O)c1C)nc1-c(cc1C)ccc1C#N RGDNMZSUCZOCPT-UHFFFAOYSA-N 0.000 description 1
- QMOWKNTVESEZCI-KZUDCZAMSA-N CCC(C)[n](c(C(NC[C@H](C)O)=O)c1CC)nc1-c(cc1)ccc1C#N Chemical compound CCC(C)[n](c(C(NC[C@H](C)O)=O)c1CC)nc1-c(cc1)ccc1C#N QMOWKNTVESEZCI-KZUDCZAMSA-N 0.000 description 1
- SRGUBDGWFICCQN-UHFFFAOYSA-N CCC(C)[n](c(C(OC)=O)c1CC)nc1-c(cc1)ccc1C#N Chemical compound CCC(C)[n](c(C(OC)=O)c1CC)nc1-c(cc1)ccc1C#N SRGUBDGWFICCQN-UHFFFAOYSA-N 0.000 description 1
- VCFGQSOYEVGCLF-UHFFFAOYSA-N CCCNC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O Chemical compound CCCNC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O VCFGQSOYEVGCLF-UHFFFAOYSA-N 0.000 description 1
- LZIQYEQHLHOHMT-UHFFFAOYSA-N CCNC(c1c(C)c(-c(cc2C)ccc2C#N)n[n]1C(C)C)=O Chemical compound CCNC(c1c(C)c(-c(cc2C)ccc2C#N)n[n]1C(C)C)=O LZIQYEQHLHOHMT-UHFFFAOYSA-N 0.000 description 1
- HFDSVNPRQSRTEF-QGZVFWFLSA-N CC[C@@H](C)CCCC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O Chemical compound CC[C@@H](C)CCCC(c1c(C2CC2)c(-c(cc2)ccc2C#N)n[n]1C(C)C)=O HFDSVNPRQSRTEF-QGZVFWFLSA-N 0.000 description 1
- MPOJUMRSSPODEY-NSHDSACASA-N C[C@@H](CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1CC1)=O)O Chemical compound C[C@@H](CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1CC1)=O)O MPOJUMRSSPODEY-NSHDSACASA-N 0.000 description 1
- LZFOQACEMDZKFI-ZYMOGRSISA-N C[C@@]1(c(cc2)ccc2C#N)NN(C2CC2)C(C(NC)O)=C1C Chemical compound C[C@@]1(c(cc2)ccc2C#N)NN(C2CC2)C(C(NC)O)=C1C LZFOQACEMDZKFI-ZYMOGRSISA-N 0.000 description 1
- MPOJUMRSSPODEY-LLVKDONJSA-N C[C@H](CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1CC1)=O)O Chemical compound C[C@H](CNC(c1c(C)c(-c(cc2)ccc2C#N)n[n]1C1CC1)=O)O MPOJUMRSSPODEY-LLVKDONJSA-N 0.000 description 1
- VLWAYOVLOXMWNO-UHFFFAOYSA-N Cc1c(C(O)=O)[n](C2CC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(C(O)=O)[n](C2CC2)nc1-c(cc1)ccc1C#N VLWAYOVLOXMWNO-UHFFFAOYSA-N 0.000 description 1
- ATKDLNMYNHUKGK-UHFFFAOYSA-N Cc1c(N)[n](C2COCC2)nc1-c(cc1)ccc1C#N Chemical compound Cc1c(N)[n](C2COCC2)nc1-c(cc1)ccc1C#N ATKDLNMYNHUKGK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/16—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9790208P | 2008-09-18 | 2008-09-18 | |
| US61/097,902 | 2008-09-18 | ||
| PCT/IB2009/054038 WO2010032200A1 (en) | 2008-09-18 | 2009-09-16 | Amide compounds useful in therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502975A true JP2012502975A (ja) | 2012-02-02 |
| JP2012502975A5 JP2012502975A5 (enExample) | 2012-10-25 |
Family
ID=41269630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011527444A Withdrawn JP2012502975A (ja) | 2008-09-18 | 2009-09-16 | 治療において有用なアミド化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8232269B2 (enExample) |
| EP (1) | EP2350017A1 (enExample) |
| JP (1) | JP2012502975A (enExample) |
| KR (1) | KR20110044304A (enExample) |
| CN (1) | CN102159548A (enExample) |
| AP (1) | AP2011005611A0 (enExample) |
| AU (1) | AU2009294290B2 (enExample) |
| BR (1) | BRPI0918935A2 (enExample) |
| CA (1) | CA2735931A1 (enExample) |
| CL (1) | CL2011000570A1 (enExample) |
| CO (1) | CO6351734A2 (enExample) |
| DO (1) | DOP2011000083A (enExample) |
| EA (1) | EA201100368A1 (enExample) |
| EC (1) | ECSP11010901A (enExample) |
| IL (1) | IL211479A0 (enExample) |
| MA (1) | MA32642B1 (enExample) |
| MX (1) | MX2011002899A (enExample) |
| PE (1) | PE20110793A1 (enExample) |
| WO (1) | WO2010032200A1 (enExample) |
| ZA (1) | ZA201102690B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5964407B2 (ja) * | 2011-04-21 | 2016-08-03 | オリオン コーポレーション | アンドロゲン受容体調節カルボキシアミド |
| EP2734042B1 (en) * | 2011-07-21 | 2017-02-01 | The Regents Of The University Of California | Targeting gli proteins in human cancer by small molecules |
| US9416109B2 (en) | 2012-02-17 | 2016-08-16 | Eisai R&D Management Co., Ltd. | Methods and compounds useful in the synthesis of orexin-2 receptor antagonists |
| EP2700635A1 (en) | 2012-08-20 | 2014-02-26 | Basf Se | 5-Trifluoromethylpyrazole amides having herbicidal activity |
| WO2014116651A1 (en) | 2013-01-23 | 2014-07-31 | The Regents Of The University Of California | Targeting gli proteins in human cancer by small molecules |
| EA027879B1 (ru) | 2013-02-22 | 2017-09-29 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK) |
| WO2014143617A1 (en) * | 2013-03-14 | 2014-09-18 | Teva Women's Health, Inc. | Deuterium-enriched tanaproget and processes for its preparation |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| US20190321363A1 (en) * | 2016-06-20 | 2019-10-24 | Dr. Reddy's Laboratories Limited | Process for the preparation of elagolix sodium and its polymorph |
| CN108623446A (zh) * | 2017-03-24 | 2018-10-09 | 北京艾德旺科技发展有限公司 | 一种合成3，3-二氟环丁烷甲酸的方法 |
| EP3946606B1 (en) | 2019-03-27 | 2025-01-01 | Insilico Medicine IP Limited | Bicyclic jak inhibitors and uses thereof |
| EP4053124A1 (en) * | 2019-10-28 | 2022-09-07 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof |
| WO2023217203A2 (zh) * | 2022-05-12 | 2023-11-16 | 西北农林科技大学 | 二苯基吡唑类化合物的制备方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604218A1 (en) * | 2005-04-20 | 2006-10-26 | Pfizer Limited | Pyrazole derivatives as progesterone receptor antagonists |
| CA2623327A1 (en) * | 2005-10-07 | 2007-04-19 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
-
2009
- 2009-09-16 KR KR1020117006161A patent/KR20110044304A/ko not_active Ceased
- 2009-09-16 JP JP2011527444A patent/JP2012502975A/ja not_active Withdrawn
- 2009-09-16 EA EA201100368A patent/EA201100368A1/ru unknown
- 2009-09-16 CN CN2009801364939A patent/CN102159548A/zh active Pending
- 2009-09-16 CA CA2735931A patent/CA2735931A1/en not_active Abandoned
- 2009-09-16 MX MX2011002899A patent/MX2011002899A/es not_active Application Discontinuation
- 2009-09-16 PE PE2011000628A patent/PE20110793A1/es not_active Application Discontinuation
- 2009-09-16 AU AU2009294290A patent/AU2009294290B2/en not_active Expired - Fee Related
- 2009-09-16 BR BRPI0918935A patent/BRPI0918935A2/pt not_active IP Right Cessation
- 2009-09-16 EP EP09787204A patent/EP2350017A1/en not_active Withdrawn
- 2009-09-16 AP AP2011005611A patent/AP2011005611A0/xx unknown
- 2009-09-16 WO PCT/IB2009/054038 patent/WO2010032200A1/en not_active Ceased
- 2009-09-17 US US12/561,398 patent/US8232269B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 IL IL211479A patent/IL211479A0/en unknown
- 2011-03-17 DO DO2011000083A patent/DOP2011000083A/es unknown
- 2011-03-17 CL CL2011000570A patent/CL2011000570A1/es unknown
- 2011-03-17 EC EC2011010901A patent/ECSP11010901A/es unknown
- 2011-03-18 MA MA33710A patent/MA32642B1/fr unknown
- 2011-03-25 CO CO11036952A patent/CO6351734A2/es not_active Application Discontinuation
- 2011-04-11 ZA ZA2011/02690A patent/ZA201102690B/en unknown
-
2012
- 2012-06-18 US US13/525,893 patent/US20120316150A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EA201100368A1 (ru) | 2011-12-30 |
| US20100249091A1 (en) | 2010-09-30 |
| CL2011000570A1 (es) | 2011-06-17 |
| PE20110793A1 (es) | 2011-10-31 |
| ZA201102690B (en) | 2011-12-28 |
| AU2009294290A1 (en) | 2010-03-25 |
| US20120316150A1 (en) | 2012-12-13 |
| AP2011005611A0 (en) | 2011-04-30 |
| EP2350017A1 (en) | 2011-08-03 |
| MA32642B1 (fr) | 2011-09-01 |
| CO6351734A2 (es) | 2011-12-20 |
| KR20110044304A (ko) | 2011-04-28 |
| AU2009294290B2 (en) | 2012-08-30 |
| IL211479A0 (en) | 2011-05-31 |
| CN102159548A (zh) | 2011-08-17 |
| US8232269B2 (en) | 2012-07-31 |
| DOP2011000083A (es) | 2011-03-31 |
| BRPI0918935A2 (pt) | 2015-12-01 |
| MX2011002899A (es) | 2011-04-11 |
| ECSP11010901A (es) | 2011-04-29 |
| WO2010032200A1 (en) | 2010-03-25 |
| CA2735931A1 (en) | 2010-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8232269B2 (en) | Amide compounds useful in therapy | |
| JP4234786B1 (ja) | ピラゾール誘導体およびその医学的使用 | |
| US10730856B2 (en) | Benzimidazole derivatives as EP4 ligands | |
| US20090099209A1 (en) | Compounds Useful in Therapy | |
| JP2010526801A (ja) | プロスタグランジンｅ２拮抗薬としてのアゼチジン誘導体およびその使用 | |
| US20080096950A1 (en) | Compounds Useful In Therapy | |
| JP2011503169A (ja) | Ｅｐ２拮抗薬としてのアゼチジン | |
| HK1156028A (en) | Amide compounds useful in therapy | |
| WO2008135824A1 (en) | Oxyalkylpyrazole compounds useful in therapy | |
| HK1124837A (en) | Pyrazole derivatives and their medical use | |
| JP2005515171A (ja) | ５−ヘテロ原子含有ピラゾールの効率的な合成法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120905 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120905 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20130404 |